NCT04219826Phase 2Completed

Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

Study sponsor: Cytokinetics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-02-28Actual
Enrollment · participants96Actual
Source updated2026-02-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events observed during dosing of CK--3773274 in patients with HCM. After: Measure: Incidence of Adverse Events (AEs) Measure: Incidence of Left Ventricular Ejection Fraction (LVEF) < 50% Measure: Incidence of Serious Adverse Events (SAEs).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview